News and Announcements
Cellmid signs evaluation and option to license agreement with Zoetis
- Published November 18, 2014 2:48PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
SYDNEY, Monday 17 November 2014
Cellmid Limited (ASX:CDY) signed an agreement with Zoetis for the evaluation and option to license one of Cellmid’s anti-midkine antibodies (MK antibody) for therapeutic use in companion animals.
To read the full announcement please download the document below.